icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
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
4ENMUpUa78ubWEaz
Listen
